Discover
IGMS
IGM Biosciences, Inc.
1.27
undefined x undefined
undefined x undefined
bid
ask
+
0.00
0.00%
04:00 PM
| Ytd | -79.21% | |
| 1y | -85.70% |
1.27
day range
1.27
6.15
52 week range
22.50
| Open | 1.30 | Prev Close | 1.27 | Low | 1.27 | High | 1.27 | Mkt Cap | 387.11M |
| Vol | 1.59M | Avg Vol | 268.09K | EPS | -3.61 | P/E | N/A | Forward P/E | -2.71 |
| Beta | 0.19 | Short Ratio | 11.22 | Inst. Own | 63.97% | Dividend | N/A | Div Yield | N/A |
| Ex Div Date | N/A | Earning | N/A | 50-d Avg | 12.15 | 200-d Avg | 10.57 | 1yr Est | 19.73 |
Earning
| Date | For | Estimate | Reported | Surprise | surprise % |
|---|---|---|---|---|---|
| 2024-11-08 | 2024-09 | -0.82 | -1.01 | -0.19 | -23.17% |
| 2024-08-14 | 2024-06 | 0.03 | -0.79 | -0.82 | -2733.33% |
| 2024-08-14 | 2024-06 | 0.03 | N/A | N/A | N/A |
| 2024-05-08 | 2024-03 | -0.84 | N/A | N/A | N/A |
| 2024-05-08 | 2024-03 | -0.84 | -0.83 | 0.01 | 1.19% |
| 2024-03-07 | 2023-12 | -1.06 | -1.01 | 0.05 | 4.72% |
Upgrade / Downgrade
| Date | Firm | Action | From | To |
|---|---|---|---|---|
| 2024-12-06 | BMO Capital | Upgrade | Outperform | |
| 2024-11-11 | Stifel | Upgrade | Buy | Buy |
| 2024-10-18 | RBC Capital | Upgrade | Outperform | Outperform |
| 2024-10-01 | Guggenheim | Upgrade | Buy | Buy |
| 2024-10-01 | Wedbush | Upgrade | Outperform | Outperform |
| 2024-10-01 | RBC Capital | Upgrade | Outperform | Outperform |
Profile
IGM Biosciences, Inc., a clinical-stage biotechnology company, develops Immunoglobulin M (IgM) antibodies for the treatment of cancer and autoimmune and inflammatory diseases. It develops Aplitabart, a Death Receptor 5 Agonist IgM antibody for the treatment of colorectal cancer; imvotamab, a CD20 x CD3 bispecific IgM antibody to treat myositis, as well as for the treatment of systemic lupus erythematosus and rheumatoid arthritis that is Phase Ib clinical trial; and IGM-2644, a bispecific T cell engaging IgM antibody targeting CD38 and CD3 proteins for the treatment of autoimmune diseases. IGM Biosciences, Inc. has a collaboration and license agreement with Genzyme Corporation to generate, develop, manufacture, and commercialize IgM antibodies. The company was formerly known as Palingen, Inc. and changed its name to IGM Biosciences, Inc. in 2010. IGM Biosciences, Inc. was incorporated in 1993 and is headquartered in Mountain View, California.
Insider Holder
| Date | Name | Relation | Quantity | Description |
|---|---|---|---|---|
| 2024-09-29 | BAKER BROS ADVISORS L.P. | Beneficial Owner of more than 10% of a Class of Security | 0.00 | Stock Award(Grant) |
| 2024-09-29 | BEHRENS M KATHLEEN | Director | 406.52K | Stock Award(Grant) |
| 2024-12-15 | DECKER LISA LYNN | Officer | 78.04K | Sale |
| 2024-12-15 | HARLER MARY BETH | Chief Executive Officer | 347.03K | Sale |
| 2024-09-29 | LEE MICHAEL STEWART | Director | 9.32K | Stock Award(Grant) |
| 2024-09-29 | REDMILE GROUP, L.L.C. | Director and Beneficial Owner of more than 10% of a Class of Security | 0.00 | Stock Award(Grant) |
Institution Ownership
| Report Date | Organization | Position | Value | Percentage |
|---|---|---|---|---|
| 2024-09-29 | Baker Bros. Advisors, LP | 4.09M | 26.64M | 12.01% |
| 2024-09-29 | Price (T.Rowe) Associates Inc | 4.01M | 26.13M | 11.78% |
| 2024-09-29 | Siren, L.L.C. | 3.33M | 21.68M | 9.77% |
| 2024-09-29 | Redmile Group, LLC | 3.07M | 20.00M | 9.02% |
| 2024-09-29 | Goldman Sachs Group Inc | 1.26M | 8.20M | 3.70% |
| 2024-09-29 | Blackrock Inc. | 899.92K | 5.86M | 2.64% |
Fund Ownership
| Report Date | Organization | Position | Value | Percentage |
|---|---|---|---|---|
| 2024-09-29 | Price (T.Rowe) New Horizons Fund | 1.97M | 12.80M | 5.77% |
| 2024-09-29 | Price (T.Rowe) Health Sciences Fund | 849.75K | 5.53M | 2.49% |
| 2024-10-30 | Fidelity Select Portfolios - Biotechnology | 809.98K | 5.27M | 2.38% |
| 2024-09-29 | Vanguard Total Stock Market Index Fund | 461.05K | 3.00M | 1.35% |
| 2024-10-30 | iShares Russell 2000 ETF | 401.29K | 2.61M | 1.18% |
| 2024-09-29 | Price (T.Rowe) New Horizons Trust | 396.15K | 2.58M | 1.16% |